Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pharmala Biotech Holdings Inc
C.MDMA
Alternate Symbol(s):
MDXXF
PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines...
: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
CSE:MDMA - Post Discussion
Pharmala Biotech Holdings Inc
> Letter to shareholders
New Post
View:
Discussion
List
(7)
•••
1991nightmaress
X
View Profile
View Bullboard History
Post by
1991nightmaress
on Jun 06, 2024 6:20pm
Letter to shareholders
https://pharmala.ca/media/2024/06/ceo-letter-to-shareholders?fbclid=IwZXh0bgNhZW0CMTAAAR2KuNQU8L5xCpGnKb3KRdl-B_pjp2NX1_zq9qMIQDmuk4_ucntrBJeGSVs_aem_AXV5I0RKDgDpqJ91O1TGsp-iZu6qZ2P8lhDAyXHLQlPYrGLPGpcl47UV5-UEJrvEdP3sNdUwLB63F4AgMrQ2CqyX
(35)
•••
polygraph46
X
View Profile
View Bullboard History
Comment by
polygraph46
on Jun 06, 2024 9:19pm
1991night: Thank you for posting the link to Nick's letter. For MDMA it's onwards and upwards. I like it...pg
(534)
•••
inviolablspirit
X
View Profile
View Bullboard History
Comment by
inviolablspirit
on Jun 07, 2024 9:54am
Nick's letter to the shareholders reiterates and confrims what I posted over the last few days. Pharmala's business has not changed with or without the panel's recommendation and in fact leads to more business opportunities for Pharmala. So if Pharmala was worth over 40 cents in the past then it is certainly worth more than what it is currently trading at. This is
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
High-grade gold potential in the world’s best mining jurisdiction
Uranium Explorer to Commence Drill Program at Clearwater West Project in Saskatchewan
Undervalued Oil & Gas Play Readies for Strong H2 2024 with Canadian and US Assets
How a truck transportation and logistics company leverages acquisitions and technology